VALUATION AND QUALIFYING ACCOUNTS (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowance, Deferred Tax Asset, Change in Amount	$ 48,406,398	[1],[2]
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	1,841,136		2,180,125		3,500,968
Charged to Costs and Expenses	1,078,195		786,107		578,805
Write-offs	(1,324,027)		(912,797)		(1,903,539)
Recoveries	55,669		16,076		3,891
Other Changes	0		(228,375)	[3]	0
Balance at End of Period	1,650,973		1,841,136		2,180,125
Valuation Allowance of Deferred Tax Assets [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	4,032,912		3,678,183		3,311,831
Charged to Costs and Expenses			354,729	[1]	366,352	[1]
Write-offs	(437,723)	[2]	0		0
Recoveries	0		0		0
Other Changes	0		0	[3]	0
Balance at End of Period	$ 52,001,587		$ 4,032,912		$ 3,678,183

[1] Related to deferred tax assets on state net operating losses and a particular subsidiary’s state portion of its deferred tax asset that arose from goodwill impairment.

[2] Related to deferred tax assets, Cyprus NOL's, and reversal of deferred tax assets related to the clinical trial services business.

[3] Represents the reclassification of the allowance for doubtful accounts related to Assets Held for Sale. See Note 3 – Assets Held for Sale and Discontinued Operations.